Therapy-Induced Senescence in Cancer Treatment: Navigating Challenges and Optimizing Combination Strategies
Despite its promise, leveraging Therapy-Induced Senescence (TIS) in cancer therapy presents several major challenges that must be addressed to optimize therapeutic outcomes. One of the most significant barriers is the heterogeneity and chronicity of the Senescence-Associated Secretory Phenotype (SASP). The composition of SASP varies not only between cell types and senescence inducers but also over time [76]. Acute SASP can be immunostimulatory, promoting immune cell recruitment and tumor clearance, whereas chronic SASP can lead to persistent inflammation, fibrosis, and the recruitment of immunosuppressive cell populations such as Tregs, M2-like macrophages, and MDSCs [122, 123]. This inflammatory and tumor-promoting shift in SASP composition can drive immune evasion, angiogenesis, and EMT, potentially facilitating tumor relapse or metastasis.
Strategies to overcome SASP heterogeneity include targeted inhibition of specific SASP regulators, such as NF-κB , p38 MAPK, or IL-1α , and the use of epigenetic modulators like EZH2 inhibitors, which have been shown to reprogram SASP toward a more immunogenic profile [124, 125].
The successful clinical deployment of senescence-targeting therapies also hinges on the development of reliable biomarkers to monitor the induction, persistence, and clearance of senescent cells in patients. Unlike apoptosis, which has clear molecular hallmarks, senescence is defined by a complex and often context-dependent signature. Traditional markers such as senescence-associated (SA)-β-galactosidase activity, p16INK4a, p21Cip1/Waf1, and SAHF are informative but lack consistency across tissue types and treatment regimens. Moreover, they do not capture the dynamic nature of senescence or its immunological impact. Recent studies have identified SASP components, non-coding RNAs, and metabolic changes as potential biomarkers, and there is growing interest in circulating DNA, extracellular vesicles, and immunopeptidomics as minimally invasive tools to track senescence in real time [126–128]. Ultimately, a multi-parametric approach combining molecular, immunological, and metabolic signatures will be essential for personalized senescence-guided therapy [129, 130]. Overall, while TIS offers a compelling framework for enhancing cancer immunotherapy, addressing the challenges of SASP heterogeneity, immune targeting specificity, and biomarker development will be essential to realizing its full therapeutic potential. These future directions will require interdisciplinary collaboration across immunology, oncology, and systems biology to develop finely tuned, clinically translatable strategies.
Potential Combination Strategies of Therapy-Induced Senescence, Immunotherapies and Senolytics
| Combination Strategy/Sequence | Primary Mechanism/Goal |
|---|---|
| TIS + oncolytic virus/in situ vaccination + senolytics | SASP enhances viral spread/immune priming; oncolytic viruses amplify antigen release and immune recruitment. |
| TIS induction → intratumoral oncolytic virus/vaccine → systemic ICI ± later senolytic | A staged approach to induce TIS, amplify antigen release and immune priming locally, followed by systemic immune checkpoint inhibition and senescent cell clearance. |
| Radiation or chemo → T-VEC/TLR agonist → anti-PD-1 → senolytic | A multi-modal sequence involving conventional therapy, oncolytic virus/TLR agonist, immune checkpoint blockade, and senolytic treatment. |
These strategies aim to elicit potent local inflammation, leading to dendritic cell maturation and systemic T-cell priming. Observed markers include a local cytokine surge, increased tumor viral load, and enhanced DC activation markers. However, a significant risk of excess inflammation exists, necessitating careful control with staged dosing and anti-inflammatory rescue plans.
TIS represents a potent but double-edged mechanism in cancer therapy—capable of halting tumor progression and enhancing immune clearance, yet equally capable of driving chronic inflammation, immune suppression, and relapse if left unchecked. Major gaps remain in our ability to precisely modulate SASP, predict senescence dynamics in patients, and determine the optimal sequencing of senescence inducers, immunotherapies, and senolytics. Future efforts should prioritize the development of robust senescence biomarkers, the dissection of non-canonical and tissue-specific senescence pathways, and the integration of systems-level and longitudinal approaches to guide patient-specific interventions. Advancing these directions will be essential to transform TIS from a partly opportunistic phenomenon into a deliberately harnessed therapeutic axis for durable cancer control.